Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
暂无分享,去创建一个
S. Ward | A. Rees | D. Hind | S Ward | E Simpson | S Davis | D Hind | A Rees | A Wilkinson | E. Simpson | E. Simpson | A. Wilkinson | S. Davis | S. Davis | Anna N. Wilkinson
[1] Wolfgang Greiner,et al. Health Technology Assessment (HTA) , 2008 .
[2] L. Curtis,et al. Unit Costs of Health and Social Care 2016 , 2015 .
[3] Wade V Welshons,et al. Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer , 2004, Cancer biology & therapy.
[4] Michael O'Leary,et al. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. , 2004, The oncologist.
[5] J. Guest,et al. The annual cost of blood transfusions in the UK , 2003, Transfusion medicine.
[6] Richard L Schilsky,et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] B. Piraccini,et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] M. Smith,et al. Systematic review of endoscopic ultrasound in gastro-oesophageal cancer. , 1998, Health Technology Assessment.
[9] Disciplinary Committee,et al. Royal Pharmaceutical Society of Great Britain , 2002 .
[10] E. Remák,et al. Cost of managing women presenting with stage IV breast cancer in the United Kingdom , 2004, British Journal of Cancer.
[11] Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Stockler,et al. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. , 2004, The Lancet. Oncology.
[13] C. Boni,et al. Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit216 multicenter phase III trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Donald A. Berry,et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer , 2006 .
[15] L. Sengeløv,et al. Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer , 1997, Breast Cancer Research and Treatment.
[16] J. Gligorov,et al. The role of taxanes in the treatment of breast cancer , 2005, Expert opinion on pharmacotherapy.
[17] T. L. Chambers. Clinical Evidence: A Compendium of the Best Available Evidence for Effective Health Care , 1999 .
[18] Mike Clarke,et al. Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.
[19] Anna L. Brown,et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] T. Bachelot,et al. Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. , 2005, JAMA.
[21] S. Schnitt,et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] J. Dettori,et al. Health technology assessment , 2009, International Journal of Technology Assessment in Health Care.
[23] S. Ward,et al. Hormonal therapies for early breast cancer: systematic review and economic evaluation. , 2007, Health technology assessment.
[24] A. Saykin,et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] K. Albain. Adjuvant chemo-endocrine therapy for breast cancer: Combined or sequential? , 2003 .
[26] Jenny C. Chang,et al. Survival of patients with metastatic breast carcinoma , 2003, Cancer.
[27] J. B. Gregg,et al. DEPARTMENT OF HEALTH. , 1910, California state journal of medicine.
[28] M. Stockler,et al. Taxane containing regimens for the adjuvant treatment of early breast cancer , 2003 .
[29] Y Wang,et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[30] L. Norton,et al. Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] J. Kleijnen,et al. The clinical effectiveness of trastuzumab for breast cancer: a systematic review. , 2002, Health technology assessment.
[32] Marek Pawlicki,et al. Adjuvant docetaxel for node-positive breast cancer. , 2005, The New England journal of medicine.
[33] M. Panella,et al. Controversies in the adjuvant treatment of breast cancer: the role of taxanes. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] S. Kümmel,et al. Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study. , 2003, Breast.
[35] R. Mannion,et al. Costs of palliative care in the community, in hospitals and in hospices in the UK. , 1999, Critical reviews in oncology/hematology.
[36] T. T. Haug,et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. , 2002, Journal of psychosomatic research.
[37] M. Westwood,et al. Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer. , 2004, Health technology assessment.
[38] M J Buxton,et al. Evaluating patient-based outcome measures for use in clinical trials. , 1998, Health technology assessment.
[39] J. Bryant,et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] U. Dafni,et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] G. Vlastos,et al. Ratios of involved nodes in early breast cancer , 2004, Breast Cancer Research.
[42] Tammy O. Tengs,et al. One thousand health-related quality-of-life estimates. , 2000, Medical care.
[43] B. Haffty,et al. Local‐Regional Breast Cancer Recurrence: Prognostic Groups Based on Patterns of Failure , 2002, The breast journal.
[44] A. Lluch,et al. Toxicity and health-related quality of life (HRQoL) in node-negative breast cancer (BC) patients (pts) receiving adjuvant treatment with TAC (docetaxel, doxorubicin, cyclophosphamide) or FAC (5-fluorouracil, doxorubicin, cyclophosphamide): Impact of adding prophylactic growth factors (GF) to TAC. GE , 2005 .
[45] M. Espié,et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] 農林水産奨励会農林水産政策情報センター,et al. The green book : appraisal and evaluation in central government , 2003 .
[47] R. Huddart,et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. , 2005, The New England journal of medicine.
[48] E. Perez,et al. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer , 2005 .
[49] R. Coleman. Current and future status of adjuvant therapy for breast cancer , 2003, Cancer.
[50] T. Delozier,et al. Safety analysis from PACS 04-A phase III trial comparing 6 cycles of FEC100 with 6 cycles of ET75 for node-positive early breast cancer patients, followed by sequential trastuzumab in HER2+ patients: Preliminary results. , 2006, Journal of Clinical Oncology.
[51] T. Bachelot,et al. Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+≤3) breast cancer (BC) patients (pts): First analysis of toxicity , 2004 .
[52] J. Ragaz,et al. Benefit of Paclitaxel in estrogen receptor-negative versus estrogen receptor-positive early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] J. Baselga,et al. European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF) , 2005 .
[54] N. Aaronson,et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] D G Altman,et al. Calculating the number needed to treat for trials where the outcome is time to an event , 1999, BMJ.
[56] I. Ellis,et al. The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.
[57] A. Ruíz,et al. Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] A. Goldhirsch,et al. Introducing taxanes in the adjuvant treatment of breast cancer: expectations and reality. , 2000, Breast.
[59] A. Leo. The European Experience with Docetaxel in the Treatment of Early-Stage Breast Cancer , 2002 .
[60] J. Abrams. North American Adjuvant Breast Cancer Trials. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.